Capra Biosciences, based in Sterling, Virginia with an additional office in Manassas, has landed continued backing from the U.S. Department of Health and Human Services to keep scaling up a technology aimed at a problem most people don’t think about until it becomes a crisis: where the raw ingredients in common medicines actually come from. The company’s total support from HHS now stands at roughly $17 million, building on a $7.5 million award it received back in July 2024.
Making Drugs With Biology Instead of Petrochemistry
Capra’s core idea is to manufacture active pharmaceutical ingredients, the actual chemical compounds inside a pill, using biology rather than traditional chemical synthesis. The company uses biofilm-forming microbes paired with proprietary, modular bioreactors that turn low-cost feedstocks into a range of chemicals. The modularity is the interesting part: the same hardware can be reconfigured to switch between producing different pharmaceutical ingredients, rather than requiring a dedicated facility built around a single molecule the way conventional chemical manufacturing usually does. Capra’s first commercial product was retinol, and the company has since validated its platform on two active pharmaceutical ingredients that are about as essential as it gets: aspirin and acetaminophen, both produced in its modular bioreactors in under two years.
What the HHS Money Is Actually Funding
The funding runs through the Administration for Strategic Preparedness and Response, HHS’s agency for public health emergency readiness, specifically via its Biomedical Advanced Research and Development Authority and the Biopharmaceutical Manufacturing Preparedness OTA Consortium, under agreement number 75A50123D00003. The original $7.5 million award funded CoMPASS, short for Continuous BioManufacturing Process Analysis for Scaling API Synthesis, a project built to prove out rapid development and scale-up of biologically derived pharmaceutical ingredients. Capra ran that work in collaboration with Google X’s A-Life team, combining the team’s AI predictions for gene and pathway expression with Capra’s own synthetic biology capabilities to speed up upstream strain engineering, alongside fellow BioMaP partner Next Rung Technology.
With aspirin and acetaminophen now validated, and the CoMPASS methodology proven out, Capra is applying those same AI-accelerated development and scale-up capabilities, built with Google X’s A-Life team and Next Rung Technology, to additional critical pharmaceutical ingredients. The company is also moving into its next phase with a new partner: the United States Pharmacopeia will help advance five of the company’s seven total API targets toward full, commercial-scale manufacturing, providing analytical development, testing, chemistry and manufacturing controls support, and regulatory assistance through its Pharmatech subsidiary.
Andrew Magyar, PhD, Capra’s co-founder and Chief Technology Officer, explained why the company thinks biology has an edge here: “Biotechnology offers tremendous power over traditional chemistry for making APIs because it is not limited by supply chains for key starting materials.”
Why Onshoring These Ingredients Matters
That line points to the real motivation behind HHS’s involvement. The announcement frames this work around bringing production of critical active pharmaceutical ingredients back onshore, ingredients the release notes are currently sourced almost exclusively overseas. Aspirin and acetaminophen are about as basic as drugs get, but that’s exactly the point: when the raw ingredients behind even the most common medicines are concentrated in a small number of overseas suppliers, a single disruption, whether from a geopolitical event, a natural disaster, or a manufacturing shutdown, can ripple into shortages of medicines hospitals and pharmacies depend on every day. A domestic, biology-based manufacturing platform that can be reconfigured across multiple essential medicines rather than being locked into one product is a direct answer to that vulnerability, and it’s exactly the kind of supply chain resilience federal health agencies have been trying to fund since the shortages and disruptions of the past several years.
For a venture-backed biotech operating out of Northern Virginia, landing sustained, multi-year federal backing to keep proving that model out is a solid vote of confidence, both in the science and in the idea that essential medicine manufacturing is worth building back in the U.S. rather than leaving offshore.
